제품 수집제품 세부정보
Specificity
Specifically recognizes Doxorubicin.
Source
Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
Clone
1M2C3
Isotype
Rabbit IgG | Rabbit Kappa
Conjugate
Unconjugated
Immunogen
Doxorubicin-BSA
Application
ApplicationRecommended UsageELISA0.06-125 ng/mLPurification
Protein A purified / Protein G purified
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Bioactivity-ELISA
Immobilized Doxorubicin-ADC at 0.1 μg/mL (100 μL/well) can bind Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216) with a linear range of 0.06-8 ng/mL (QC tested).
Protocol
Serial dilutions of Doxorubicin were added into Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216): Doxorubicin-ADC binding reactions. The half maximal inhibitory concentration (IC50) is 0.009186 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216) with Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Doxorubicin specific Antibody, Rabbit IgG (1M2C3) (Cat. No. DON-MY2216) is specific to Doxorubicin-ADC and has no cross-reactivity with IgG1-MMAF, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
사용자 리뷰 댓글 남기기
배경 소개
프론티어 진행
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
